about
c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells.Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy.BRCA1: a novel prognostic factor in resected non-small-cell lung cancerA core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum responseThe prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia.MYC in breast tumor progressionMYC and Breast Cancer.MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancersMutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.A mouse model for the molecular characterization of brca1-associated ovarian carcinomac-myc amplifications in primary breast carcinomas and their local recurrences.Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.Advances in breast cancer: pathways to personalized medicineMYC amplification in breast cancer: a chromogenic in situ hybridisation studyBRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.The mammalian ovary from genesis to revelation.Enigmatic MYC Conducts an Unfolding Systems Biology Symphony.BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potentialThromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women.
P2860
Q31018068-7A150F06-D07A-49EF-AAAA-CE4F5A962EA6Q31114634-21501813-7C06-47E3-9CA6-495B3869C192Q33305206-BB432CE1-9028-4E65-BE16-D789B9235510Q33494820-A3F8DF04-B42D-4F4B-AE7F-4B4027D35927Q33538053-B438276A-A382-4C3E-9550-25F3C7A140FCQ33996661-EF7DFB34-6CDB-4F8D-BD1E-AAF7274D87ECQ34524915-77F1E73A-CF3C-4981-B25B-D77D16381BE3Q34972381-5137399B-2310-4BD3-85A2-7301ADF6E6A3Q34991267-3ADF4F4A-26DE-4010-AE68-A2DF8E87D420Q35470405-DA5E3CFD-B50D-4EA6-BDC9-AD0AB5A734D0Q35646878-21C72DEA-3998-46A8-A57E-FB8C08245C1FQ35769894-8BDA9068-A4B6-4334-AA9A-2D47B4A4CC08Q35794363-2F1AD736-0FF5-4749-BC41-8EE733E27715Q35951346-5BB04E6F-2EC3-4A2D-BFA3-98E06335A076Q35984487-98A30E5B-3616-4907-9F91-A6481C1097C0Q36402747-BB7480BB-7681-43BE-9B51-170543E5E29DQ37128739-7E90D2DA-5AE1-4844-8C87-EE5438BC5FB7Q37385514-80DCFFFD-4221-4814-AA61-97FB73A7E9C9Q37827073-100E98EC-A0EB-4AAB-8B70-054548538AE7Q40907759-19FED97F-7163-433C-B1AE-1A6C47EFCDD5Q42317506-C779D9C5-E816-4C18-ABD6-50FB7BB6F09BQ48588785-9ED4FC4A-C239-4409-A79B-A641D5D1D629Q53687423-9CA683EE-A79F-451C-8E45-EF830BA16295
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
MYC is amplified in BRCA1-associated breast cancers.
@en
MYC is amplified in BRCA1-associated breast cancers.
@nl
type
label
MYC is amplified in BRCA1-associated breast cancers.
@en
MYC is amplified in BRCA1-associated breast cancers.
@nl
prefLabel
MYC is amplified in BRCA1-associated breast cancers.
@en
MYC is amplified in BRCA1-associated breast cancers.
@nl
P2093
P1476
MYC is amplified in BRCA1-associated breast cancers.
@en
P2093
Anne M Blackwood
April J Adams
Barbara L Weber
Fitsum G Hagos
Henry T Lynch
James J Dignam
Karin K Ridderstråle
Kristin N Anderson
Lise Sveen
Min-Jie Wei
P304
P356
10.1158/1078-0432.CCR-0976-03
P407
P577
2004-01-01T00:00:00Z